International Youth Day.

Young people today face growing mental health challenges, and depression remains one of the most common.​ This International Youth Day, we're raising awareness about treatment options for adolescents living with major depressive disorder.​ For adolescents ages 15–21 who continue to experience depression symptoms, NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option. Clinical data show meaningful improvement and remission rates in adolescents treated with NeuroStar.*​ Awareness can lead to conversations. Conversations can lead to support. And support can make all the difference. 💜​ Schedule a consultation to learn more about NeuroStar TMS therapy. #InternationalYouthDay #MentalHealth #NeuroStarProvider @neurostaradvancedtms *1. FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ‡ 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. "Measurable relief" was defined as a CGI-S score ≤3 and "complete remission" was defined as a CGI-S score ≤2 at the end of treatment.

Young people today face growing mental health challenges, and depression remains one of the most common.​ This International Youth Day, we're raising awareness about treatment options for adolescents living with major depressive disorder.​ For adolescents ages 15–21 who continue to experience depression symptoms, NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option. Clinical data show meaningful improvement and remission rates in adolescents treated with NeuroStar.*​ Awareness can lead to conversations. Conversations can lead to support. And support can make all the difference. 💜​ Schedule a consultation to learn more about NeuroStar TMS therapy. #InternationalYouthDay #MentalHealth #NeuroStarProvider @neurostaradvancedtms *1. FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ‡ 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. "Measurable relief" was defined as a CGI-S score ≤3 and "complete remission" was defined as a CGI-S score ≤2 at the end of treatment.

Young people today face growing mental health challenges, and depression remains one of the most common.​ This International Youth Day, we're raising awareness about treatment options for adolescents living with major depressive disorder.​ For adolescents ages 15–21 who continue to experience depression symptoms, NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option. Clinical data show meaningful improvement and remission rates in adolescents treated with NeuroStar.*​ Awareness can lead to conversations. Conversations can lead to support. And support can make all the difference. 💜​ Schedule a consultation to learn more about NeuroStar TMS therapy. #InternationalYouthDay #MentalHealth #NeuroStarProvider @neurostaradvancedtms *1. FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ‡ 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. "Measurable relief" was defined as a CGI-S score ≤3 and "complete remission" was defined as a CGI-S score ≤2 at the end of treatment.